Functional Outcomes of a Comprehensive, Individualized, Person‐Centered Management Program in Advanced Alzheimer’s Disease(AD): Results from a 52‐Week Randomized Controlled Trial

We conducted a 28‐week, single‐blind, randomized, controlled trial of the efficacy of Comprehensive, Individualized, Person‐Centered Management (CI‐PCM) and memantine treatment (Reisberg et al., Dement Geriatr Cogn Disord, 2017) in advanced AD persons. CI‐PCM and memantine was approximately 7.5 times more beneficial to AD persons on the Functional Assessment Staging Tool (FAST) (Kenowsky et. al., Alzheimer’s and Dementia, 2017) than to AD persons who received memantine alone in the memantine FDA approval pivotal trial conducted by Reisberg et. al., (NEJM 2003). We also conducted a 24‐week extension study. Herein, we report the difference in functional outcomes between the CI‐PCM and Usual Community Care (UCC+FC) groups at 52‐weeks on the FAST and the ADCS‐ADLSev‐Abv. See Figures 1 and 2.